French Healthcare
BIO International Convention
June 2022
<table>
<thead>
<tr>
<th><strong>4P-PHARMA</strong></th>
<th><strong>AMOLYT PHARMA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P is the dual leverage of in-house R&amp;D capabilities combined with single product vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.</td>
<td>We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ADMEDICA</strong></th>
<th><strong>ANS BIOTECH</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Addmedica is a fast growing company focused on developing and marketing medical products for: • rare diseases • unmet medical needs in developed and emerging countries • serious conditions Addmedica is dedicated to providing high medical value to physicians, patients, and managed care organizations, by developing, registering and marketing a wide range of medical products in several rare and debilitating diseases.</td>
<td>ANS Biotech is an independent preclinical Contract Research Organization exclusively dedicated to the pharmacology of pain. As a close Pharma and Biotech partner, ANS Biotech offers its clients a unique combination of exceptional expertise in the fundamentals of pain pharmacology as well as a proven record of R&amp;D program management for new and innovative analgesics. All along the building of the preclinical dossier, ANS Biotech services are performed in compliance with the highest ethical and quality standards.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>AFFILOGIC</strong></th>
<th><strong>APMONIA THERAPEUTICS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Affilogic is a private biotech company specialised in discovering and developing biopharmaceuticals with Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.</td>
<td>Apmonia Therapeutics is a biotechnology company developing innovative therapeutic strategies against various cancers.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ALGOTX</strong></th>
<th><strong>APTAR PHARMA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AlgoTherapeutix develops innovative solutions for complex pain. ATX01 is entering Phase II in chemotherapy-induced peripheral neuropathy and erythromelalgia. AlgoTx's conference focus is to meet investors in its 20 ME Series B and partners for regional R&amp;D partnerships.</td>
<td>Aptar Pharma is the go-to drug delivery expert, from formulation to patient, for proven solutions, packaging and services to the Pharma industry. Using engineering and science, we bring innovative technologies to the market that improve the lives and health of millions of people worldwide.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ALIRA HEALTH</strong></th>
<th><strong>APTYSS PHARMA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle, from development to medical care, through real-world evidence.</td>
<td>Aptyss pharma includes one design laboratory equipped to carried out preformulation and innovative formulation studies and one GMP laboratory specialized in analytical development, quality control and ICH stability studies.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ATLANTHERA</strong></th>
<th><strong>ATLANTHERA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments.</td>
<td>Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments.</td>
</tr>
</tbody>
</table>
AUDIT & RISKSOLUTIONS
As an insurance broker specializing in corporate risk management, Audit & Risksolutions has developed since its creation a specific expertise in the field of Life Sciences and Finance.

AXOLTIS PHARMA
Axoltis Pharma is a biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.

BIOPHYTIS
Biophytis is a French clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases (lead development program is Sarcopenia, Biophytis is on track to initiate a Ph3 program), including severe respiratory failure in patients suffering from COVID-19 (Ph2/3 being completed with EUA targeted 2022).

BIPER THERAPEUTICS
Biper TX is a biotech start-up developing first-in-class drug candidates against cancers with high unmet medical needs. Our first drug candidate, BPR001 is at 18 months from the clinic and has been developed to treat gastro-intestinal cancers in oral administration. We are a seasoned team of biotech and academic experts leveraging more than 10 years of extensively awarded research in metabolism of cancer cells.

BRENUS PHARMA
Brenus Pharma is a French private biotech co-founded by a serial entrepreneur in healthcare and an expert in GMP manufacturing of cells for human use. Brenus is managed by an executive team of scientific and business members, supported by top WW academics in US and EU. A business board will be disclosed in coming weeks.

CAPEVAL PHARMA SARL
CapEval Pharma is an independent company providing development, registration as well as teaching services in the fields of pharmaceuticals, veterinary drugs and oncology. The key experience and proficiency of its scientists specialized in various fields of expertise consist of assessment, selection and management of oncology drug development projects, due diligence assistance and implementation, ocular examination, cardiovascular examination, medical writing, scientific translations, public subvention dossiers, fundraising and implementation and development of marketing partnerships.

CLEAN CELLS
Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

CROSSJECT
Crossject is a France-based specialty pharma, pioneering an innovative prefilled needle free auto-injector, ZENEO® which injects intramuscularly or subcutaneously a drug in only two steps (Place & Push onto the injection site). The full dose is delivered in less than 1/10th of a second.

DA VOLterra
Headquartered in Paris (France), Da Volterra is a clinical-stage biopharmaceutical company pioneering a new therapeutic class: gut protectors in oncology.

DEFYMED
Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of ‘therapeutics’ administration. 2 first in class technologies were developed by Defymed: MailPan, a physiologic cell encapsulation device, and ExOSh, a targeted drug delivery device.
FRENCH HEALTHCARE DELEGATION AT THE BIO INTERNATIONAL CONVENTION

**DYNA-CURE**
Dynacure is a clinical-stage biotechnology company developing new treatments for patients affected by serious orphan disorders. Its first clinical program is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery. Dyn101 program is in clinical development since Q1 2020 with a multi-centered Phase 1/2 in Europe (Unite-cnrm). Dynacure was founded in 2016 as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg.

**EGLE THERAPEUTICS**
A spin-out from Institut Curie established in 2020, backed by €40 million Series A and a research collaboration with Takeda, Egle Therapeutics is an emerging biotechnology company focused on the development of first-in-class immunotherapies targeting immune suppressive Treg cells (Treg) for oncology and autoimmune diseases. The key element of Egle’s core approach is based on a platform for the discovery of novel solid tumor-specific Treg targets, coupled with specific modulators of Treg immunosuppressive activity, also known as Treg starvers or Treg engagers.

**ETABLISSEMENT FRANÇAIS DU SANG**
Established on 2000, EFS is the unique civil operator of blood transfusion in France, under the authority of the French Ministry of Health. The core mission of EFS is to ensure national self-sufficiency in labile blood products under optimal conditions of safety and quality. The EFS is organized into 13 regional blood transfusion establishments. EFS is also the leading biomedical laboratory in France. EFS laboratories carry out different types of biological analyses which are designed to ensure product safety in the context of transfusions, but also in organ, tissue or cell transplants. By checking the compatibility of the characteristics of the recipient with those of the blood products intended for him or her, EFS has recognised expertise in immunohematology and immunogenetics. EFS is France’s leading producer of advanced therapy medicinal products (ATMP) for phase 1 and 2 clinical trials. EFS is a partner for the production of in vitro diagnostic medical devices at its reagent production unit. EFS carries out research activities in cutting-edge fields, contributing to scientific and medical advances in fields related to transfusion activities: research into blood cells, cell and tissue therapy, immunology, microbiology, and clinical research. EFS is looking for new academic and industrial partners to set up scientific collaborations and licensing opportunities.

**ETAP-LAB**
ETAP-Lab is a leading preclinical CRO for 30 years, offering relevant research services in the fields of Dermatology, Health-Nutrition and Neurology, especially in stroke and neurodegenerative diseases, aimed at evaluating drug and medical device efficacy.

**FABEN-TECH**
Founded in 2009, Fabentech is a French biotech company specialized in the development and production of polyclonal antibodies intended for treating emerging infectious diseases and intoxications. Fabentech’s pipeline includes H5N1, Ebola, CCHF, Biodefense and Covid-19 indications.

**FIRALIS**
Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services.

**GENOSKIN**
Genoskin provides hi-tech alternatives to animal testing. Our test models use human skin samples, obtained with the informed consent of the donors. Our patented technology keeps the samples alive in wells to study skin reactions to the products being tested.

**GENOWAY**
genOway’s activities focus on customized mouse, rat and cell line genetical modifications by combining technologies routinely used in genome engineering (Knockout, conditional Knockout, Knockin, humanization, point mutations, overexpressions, etc.) with a range of innovative technological solutions to create a new generation of models of higher physiological relevance.

**GENSIGHT**
GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Developed as a treatment for LHON, our lead product candidate LUMEVOQ® is currently under review for MA approval by EMA.

**HTL BIOTECHNOLOGY**
HTL biotechnology is a worldwide biopolymer platform, with recognized R&D and manufacturing capacities, bringing innovative medical solutions to the healthcare industry.

**INOVARION**
Inovarion is a research center in Life Sciences which has established itself in a few years as a key player in research and development in France. Inovarion develops in-house research projects and supports its clients from an operational point of view at each stage of their research projects. Inovarion has conducted more than 250 research projects and has more than 100 publications in the most prestigious journals (Science, Nature, Cell, The Lancet ...).
INOVIEM SCIENTIFICS
Inoviem Scientific SAS is a contract research biotech which offers preclinical and clinical services based on Label free proprietary technologies (NPOT®, PIMS®) to secure and speed up your drug-development from Lead selection/ Target ID to your clinical phases Ph 3.

INOVIATION
INOVIATION evaluates earlier in vivo efficacy and toxicity for anti-cancer treatments in monotherapy or in combo with standard of care (chemotherapy, radiotherapy, or immunotherapy). An in vivo Multi-Cancer Screening to (re)positioning your drugs is now possible.

INSTITUT CARNOT
A world-renowned university hospital with a European dimension. 38 hospitals welcoming every year more than 10 million sick people: in consultation, in emergency, during scheduled hospitalizations or in hospitalization at home, at all ages of life. Provides a public health service for all, 24 hours a day.

IRIS PHARMA
Not just an ophthalmology-focused contract research organization (CRO), Iris Pharma helps clients around the world navigate every stage of the drug and medical device development process and delivers customized solutions.

KINATHERA
Kinathera is a seed stage preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders such as systemic scleroderma or GvHD.

LYS THERAPEUTICS
Lys Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from neurovascular or neurodegenerative disorders, including stroke and multiple sclerosis. Its main drug is a first-in-class monoclonal antibody, Glunozumab®, with an exclusive and groundbreaking mechanism of action.

MAAT PHARMA
To address major unmet medical needs in oncology, MaaT Pharma is designing a groundbreaking and innovative therapeutic approach based on gut microbiome modulation. The company develops high-richness and high-diversity drug candidates derived from healthy donors (MaaT013 and MaaT033) or produced by co-fermentation (MaaT03X), using its Microbiome Ecosystem Therapy proprietary platform.

MABDESIGN
MabDesign is a French membership organization that aims to structure, mobilize and support the development of the French industrial sector in the field of biotherapy. MabDesign provides strategic leverage and development opportunities for its members. These initiatives include:
- a web directory of immunotherapy stakeholders allowing the identification of expertise and potential partners;
- access to innovative training solutions;
- business development and marketing support;
- IP analysis;
- organisation of events promoting innovation and networking.

MABLINK BIOSCIENCE S.A.S.
Mablink Bioscience is specialized in the development of antibody-drug conjugates (ADCs). Its patented hydrophilic linker technology PSARlink™ enables the design of homogenous, plasma-stable, next generation high DAR ADCs with excellent pharmacological properties.

MCASF
The French deeptech McSAF develops innovative technology platforms for next generation antibody-drug conjugates (ADCs) in oncology. Our business model is to offer turnkey services for the design and screening of ADC candidates and to license our proprietary technologies. We are also beginning development of our first proprietary product in onco-dermatology.

MEDINCELL
MedinCell® is a pharmaceutical company at premarketing stage that develops innovative LAI in many therapeutic areas. Our Products are based on our BEPO® technology and aim to ensure patient compliance, improve the effectiveness & accessibility of treatments, and reduce their environmental footprint.
FRENCH HEALTHCARE DELEGATION AT THE BIO INTERNATIONAL CONVENTION

NAOBIOS
Naobios is CDMO specialized in the process development and GMP manufacturing of viral vaccines, viral vectors and oncolytic viruses.

NETRI
NETRI is an industrial start-up developing innovative technologies for the pharmaceutical industry. Its patented organ-on-chip technologies allow the creation of standardized and predictive human in vitro models. This allows to anticipate the efficacy of an innovative treatment, to accelerate preclinical research phases, and to reposition compounds on new indications, while limiting animal testing. The use of human neural circuits coupled with multiple cell types opens the way to more personalized medicine as well as faster and more relevant diagnostics. Current application areas include neurological disorders, cosmetics and nutrition.

NETRIS PHARMA
NETRIS Pharma is the first spin-off of Centre Léon Bérard In Lyon, and based on 20 years of research conducted by Patrick Mehlen on the role of Dependence Receptors. The Company is currently sponsoring a multicentric Phase2 clinical trial in combination with chemo and Pneborizumab over 240 patients.

NEURON EXPERTS
Neuron Experts is a private CRO, created in 2008, specialized in cultures of neurons mimicking neurodegenerative diseases. It is located in Marseille, France, where it has 250 m² of independent laboratory. 80% of its turnover is exported.

NETRIS ALLIANCE
Neuroservices-Alliance is a CRO focused on providing the pharmaceutical industry with preclinical solutions to help advance drug discovery for Central Nervous System diseases and Pain. Neuro-pharmacological readouts are generated from in vitro & in vivo CNS & Pain Electrophysiology and Behavioral tests.

NICOX
Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health. We are maximizing value by advancing our product candidates to approval in the US & EU, optimizing their development and commercialization elsewhere with partnering.

FRENCH HEALTHCARE DELEGATION AT THE BIO INTERNATIONAL CONVENTION

NOSOPHARM
Nosopharm is an innovative biotechnology company specialized in anti-infective drug discovery. Nosopharm is the only biotech company to explore the antimicrobial-producing bacteria Photorhabdus and Xenorhabdus for anti-infective applications.

NOVA DISCOVERY
NOVA is a leading Healthtech company which simulates in silico clinical trials in virtual patient populations for bio-pharma companies with a need to accelerate and de-risk their R&D. With over a decade of experience and multiple commercial projects with biotech and pharma companies, NOVA has developed a unique in silico trial simulation platform called JINKO.

ONCODESIGN
Oncodesign is a leading biopharmaceutical company that meets the needs of innovation in the health industry through precision medicine. The company has built an industrial model of innovation to orientate new therapeutic molecules to fight cancer & other serious illnesses with unmet medical needs.

PAR’IMMUNE
Par’Immune is a biotech company founded in 2017 and based in Lille, France. The company’s programs are dedicated to the development of new patent protected therapeutic strategies towards Immune Mediated Inflammatory Diseases (IMIDs) based on the recombinant P28GST drug-candidate.

PHOST’IN THERAPEUTICS
Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases.
SEQENS

SEQENS is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients leveraging on 24 manufacturing sites, 10 R&D centers and 3,200 employees in 10 countries. As an integrated player across the value chain - from raw materials to active ingredients and pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Driven by a culture of excellence and a strong entrepreneurial spirit, but also strong values such as unity, tenacity, agility and reactivity, our employees are committed to providing more than best available technologies. In the pharmaceutical industry, Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. Seqens also offers a large portfolio of APIs and proprietary products.

PROTEOGENIX

ProteoGenix is a biotech contract research organization (CRO) providing flexible end-to-end solutions for the discovery and development of life-saving biopharmaceuticals, advanced diagnostics tools, and high-quality biological reagents. Drawing from 28+ years of experience in biologics discovery, bioproduction, and engineering, the company specializes in maximizing the developability and efficacy of new biomolecules. With 3 antibodies on the market and 30+ in clinical and preclinical trials, ProteoGenix’s mission is to create and optimize solutions to put biopharmaceuticals on the fast track to the clinic.

PROFILEHIT

ProfileHIT is a French CRO specialised in the discovery and identification of new active ingredients/drug candidates’ properties with a multiparametric approach by flow cytometry. Through an innovative approach, ProfileHIT brings an early access to the biological potential of new molecules.

PORSOlt SAS

Porssol is a global preclinical CRO with almost 40 years of experience, providing preclinical discovery, efficacy, and safety pharmacology services. We also provide GLP services in multiple species, including rodents, rabbits, guinea pigs, ferrets, minipigs, and dogs.

SYNDIVIA

Syndivia is devoted to confronting the most challenging cancer indications by developing novel targeted antibody-based therapeutics. By combining its unique proprietary technologies for specific targeting of tumour hallmarks and microenvironment with selected mono-clonal antibodies, Syndivia's team has a track record of successful licensing deals, spin-offs and proprietary development programs.

THEranexus

Theranexus, a unique clinical stage pharmaceutical company, has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.

STEminov

Steminov is a clinical stage spin-off from CHRU of Nancy and University of Lorraine (UL) that develops an off the shelf cell therapy treatment in the field of inflammatory pathologies with unmet medical need. Based on a robust clinical package and largely admitted safety of the treatment, Steminov is preparing a first in human clinical trial. To face the challenge of WJ-MSC supply and master the process and quality of our drug candidate, we have decided to generate internal know-how on the 3D production of these cells and to set up the first European WJ-MSC 3D production unit (based on bioreactors and microcarriers).

SYNAPCELl

Founded in 2005, SynapCell uses translational EEG biomarkers for CNS disorders, to deliver objective decision-making endpoints to international biopharmaceutical companies across a wide range of therapeutic areas including Epilepsy, Parkinson's Disease or Psychiatric disorders.

STEMINov SAS

Steminov is a global preclinical CRO with almost 40 years of experience, providing preclinical discovery, efficacy, and safety pharmacology services. We also provide GLP services in multiple species, including rodents, rabbits, guinea pigs, ferrets, minipigs, and dogs.

SYNAPCELL

SynapCell uses translational EEG biomarkers for CNS disorders, to deliver objective decision-making endpoints to international biopharmaceutical companies across a wide range of therapeutic areas including Epilepsy, Parkinson's Disease or Psychiatric disorders.

SYNDIVIA

Syndivia is devoted to confronting the most challenging cancer indications by developing novel targeted antibody-based therapeutics. By combining its unique proprietary technologies for specific targeting of tumour hallmarks and microenvironment with selected mono-clonal antibodies, Syndivia's team has a track record of successful licensing deals, spin-offs and proprietary development programs.

THERANEXUS

Theranexus, a unique clinical stage pharmaceutical company, has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.

TRANSUCRe BIOSERVIVES

TransCure bioServices is your one-stop turnkey provider of in vivo pharmacology preclinical services. We are the only fee-for-service global CRO specializing in fully humanized immune system and liver mouse models for the study of diseases such as cancer, infectious diseases, and inflammation, among others. Our team has developed strong data-driven proficiency in predictive advanced mouse models with 100% functional reconstitution of the full human immune system in severely immunodeficient mice, and 100% human hepatocytes reconstitution in a humanized liver mouse model. We provide qualified services offering first-rate results and are data-driven experts in these platforms:
- Fibrotic Diseases Including Asthma and NAFLD/NASH
- Graft-vs-Host Disease (GvHD)
- HIV, Viral Hepatitis & Other Infectious Diseases
- Inflammatory Bowel Disease (IBD)
- Oncology & Immuno-Oncology Including PDX and CDX Models
- Vaccines & Immunization
VALNEVA
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with over 600 employees.

VAXXEL
Vaxxel develops live-attenuated viruses as intranasal vaccine-candidates against Metapneumovirus and against Respiratory Syncytial Virus based on the versatile proprietary Metavac® vaccine platform. Proof of Concept of the first intranasal monovalent vaccine candidate against Metapneumovirus has been demonstrated on both animal and human ex-vivo models. Vaxxel’s vaccine candidates address a market exceeding 5 billion euros for which there is currently no licensed vaccine.

VECT-HORUS
Vect-Horus endorses a mixed business model, based on its proprietary VECTrans® technology, both to make its technology platform available to pharmaceutical and biotechnology company partners and to develop an internal pipeline of products. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. Based in Marseille, France, the company has 35 employees, mostly in R&D, and develops academic collaborations with the CNRS and AMU as well as industrial partnerships.

VOISIN CONSULTING
VCLS is a global regulatory science and clinical research consultancy firm, which guides biotechnology, pharmaceutical and MedTech manufacturers throughout product development and market access. From early-stage to patients, VCLS assists innovators by designing product development strategies that optimize clinical development to drive commercial success. The firm offers integrated solutions with regulatory and market access development strategy, chemistry formulation, manufacturing scale-up & control services, nonclinical & clinical regulatory development planning, clinical trial operations, safety monitoring and data management. With offices in Cambridge, and Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark), Antananarivo (Madagascar), Bangalore (India) and Shanghai (China), VCLS serves a broad range of developers and investors in life sciences.

YPOSKEKI
Yposkesi, an SK pharmteco company, is one of Europe’s largest CDMO offering a full range of services in viral vector cGMP manufacturing for gene therapy. The company employs ~200 persons and is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

YSOPIA BIOSCIENCE
YSOPIA Bioscience is a French clinical stage biotech company specializing in the research and development of therapeutic innovations harnessing the potential of the gut microbiome. YSOPIA develops groundbreaking biotherapies using single-strain keystone bacteria. The Company has successfully completed a Phase 1 clinical trial evaluating its drug-candidate, Xla1, in people suffering from obesity and associated metabolic disorders. YSOPIA’s portfolio also includes additional innovative programs in several indications with substantial unmet medical needs, such as Crohn’s disease, mood disorders or oncology. Supported by leading venture capital investors, such as Seventure Partners, and family offices, YSOPIA Bioscience has established collaborative projects worldwide with renowned scientific institutions and academic experts to maintain the highest standards in the development of its innovative biotherapeutics. YSOPIA Bioscience is an active member of the Alliance Promotion Microbiote, an initiative bringing together many industrial groups, competitiveness clusters and research organizations to promote the microbiota sector and to position France as a European leader in the field.
French Healthcare is an innovative public-private initiative aimed at bringing together all the players in the French healthcare ecosystem (businesses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world. This initiative is supported by the Ministry for Europe and Foreign Affairs, the French Healthcare Association and Business France.

Choose France is a registered trademark of the French government that promotes France’s economic attractiveness internationally.

Produced by Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.

Business France has 1,500 personnel, both in France and in 55 countries throughout the world, who work with a network of partners. Since January 2019, as part of the reform of the state support system for exports, Business France has given private partners responsibility for supporting French SMEs and mid-size companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines and Singapore.